ATE538092T1 - Asparaginsäureproteaseinhibitoren - Google Patents
AsparaginsäureproteaseinhibitorenInfo
- Publication number
- ATE538092T1 ATE538092T1 AT06837406T AT06837406T ATE538092T1 AT E538092 T1 ATE538092 T1 AT E538092T1 AT 06837406 T AT06837406 T AT 06837406T AT 06837406 T AT06837406 T AT 06837406T AT E538092 T1 ATE538092 T1 AT E538092T1
- Authority
- AT
- Austria
- Prior art keywords
- protease inhibitors
- acid protease
- asparagic acid
- asparagic
- inhibitors
- Prior art date
Links
- 108091005508 Acid proteases Proteins 0.000 title 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 title 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 title 1
- 229960005261 aspartic acid Drugs 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73656405P | 2005-11-14 | 2005-11-14 | |
| US84533106P | 2006-09-18 | 2006-09-18 | |
| US84529106P | 2006-09-18 | 2006-09-18 | |
| PCT/US2006/043920 WO2007070201A1 (en) | 2005-11-14 | 2006-11-13 | Aspartic protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE538092T1 true ATE538092T1 (de) | 2012-01-15 |
Family
ID=37812974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06837406T ATE538092T1 (de) | 2005-11-14 | 2006-11-13 | Asparaginsäureproteaseinhibitoren |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8487108B2 (enExample) |
| EP (1) | EP1966139B1 (enExample) |
| JP (1) | JP2009515893A (enExample) |
| KR (1) | KR101379663B1 (enExample) |
| AR (1) | AR057890A1 (enExample) |
| AT (1) | ATE538092T1 (enExample) |
| AU (1) | AU2006325322B2 (enExample) |
| BR (1) | BRPI0618585A2 (enExample) |
| CA (1) | CA2628952C (enExample) |
| NO (1) | NO20082108L (enExample) |
| NZ (1) | NZ568042A (enExample) |
| PE (2) | PE20070804A1 (enExample) |
| SG (1) | SG169983A1 (enExample) |
| TW (1) | TWI411607B (enExample) |
| WO (1) | WO2007070201A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0516132A (pt) | 2004-10-07 | 2007-12-04 | Vitae Pharmaceuticals Inc | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica |
| US20090275581A1 (en) * | 2006-04-05 | 2009-11-05 | Baldwin John J | Renin inhibitors |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| WO2007117560A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
| EP2010488A2 (en) * | 2006-04-05 | 2009-01-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| JP2010503682A (ja) * | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
| WO2009038719A1 (en) * | 2007-09-17 | 2009-03-26 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
| WO2009038715A1 (en) * | 2007-09-17 | 2009-03-26 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| CN102088850A (zh) * | 2008-06-26 | 2011-06-08 | 生命医药公司 | 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐 |
| US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
| DK2308877T3 (da) | 2008-08-05 | 2014-04-22 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-on-derivater |
| WO2010111634A2 (en) * | 2009-03-26 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| WO2012081582A1 (ja) * | 2010-12-15 | 2012-06-21 | 国立大学法人北海道大学 | ジアステレオ選択的にアルコール化合物を製造する方法及びルテニウム化合物 |
| WO2012081585A1 (ja) * | 2010-12-15 | 2012-06-21 | 国立大学法人北海道大学 | 光学活性アルコール化合物の製造方法 |
| BR112015003393A2 (pt) | 2012-08-16 | 2017-07-04 | Janssen Pharmaceutica Nv | pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CA3173676A1 (en) * | 2020-04-24 | 2021-10-28 | Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. | A formulation for treating ophthalmic conditions |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| AR129265A1 (es) | 2022-05-12 | 2024-08-07 | Syngenta Crop Protection Ag | Compuestos de alcoxi-heteroaril-carboxamida o tioamida |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
| CN116987090B (zh) * | 2023-07-25 | 2025-06-27 | 乳源东阳光药业有限公司 | (4aR,7aS)-6-(2,2-二乙氧基乙基)六氢-5H-[1,4]二恶烷并[2,3-c]吡咯的合成方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3071618A (en) | 1956-02-02 | 1963-01-01 | Pfizer & Co C | Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines |
| GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
| US4136163A (en) | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
| JPS5115098A (ja) | 1974-07-26 | 1976-02-06 | Asahi Chemical Ind | Akurirukeiseniseihinno shorihoho |
| US4594343A (en) * | 1984-10-19 | 1986-06-10 | Shanklin Jr James R | 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles |
| GB8810067D0 (en) | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
| US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| DE4018070A1 (de) | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
| EP0561973A1 (en) | 1990-12-14 | 1993-09-29 | Merrell Dow Pharmaceuticals Inc. | Antiallergic compounds |
| DE69330823T2 (de) | 1992-02-13 | 2002-05-02 | Merrell Pharmaceuticals Inc., Cincinnati | Thiacyclische piperidinylderivate |
| EP0773921B1 (en) | 1994-07-29 | 1999-12-01 | Abbott Laboratories | Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| CA2291157A1 (en) | 1997-05-29 | 1998-12-03 | Eli Lilly And Company | Process for preparing heterocyclic compounds |
| AU3716499A (en) | 1998-04-21 | 1999-11-08 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| GB9826540D0 (en) | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
| US6613764B1 (en) * | 1999-01-06 | 2003-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Aspartic protease inhibitors |
| JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | Ｎ−置換ピペリジン誘導体 |
| OA12323A (en) | 2000-03-21 | 2006-05-15 | Smithkline Beecham Corp | Protease inhibitors. |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| AU2002320490B2 (en) | 2001-07-11 | 2008-10-02 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| AR039555A1 (es) * | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
| TW200408645A (en) | 2002-04-26 | 2004-06-01 | Gilead Sciences Inc | Non nucleoside reverse transcriptase inhibitors |
| WO2004002483A1 (en) * | 2002-06-27 | 2004-01-08 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease |
| US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| AU2003273310A1 (en) | 2002-09-10 | 2004-04-30 | Pharmacia And Upjohn | Substituted aminoethers for the treatment of alzheimer's disease |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| CA2576971A1 (en) | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| BRPI0516132A (pt) * | 2004-10-07 | 2007-12-04 | Vitae Pharmaceuticals Inc | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica |
| EP1882684B1 (en) | 2005-05-19 | 2014-12-10 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| WO2007117560A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| JP2010503682A (ja) | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
| US20100160424A1 (en) | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| WO2009096996A1 (en) | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
| US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
| WO2009154766A1 (en) | 2008-06-20 | 2009-12-23 | Vitae Pharmaceuticals, Inc. | Renin inhibitors and method of use thereof |
| CN102088850A (zh) | 2008-06-26 | 2011-06-08 | 生命医药公司 | 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐 |
| AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
-
2006
- 2006-10-31 TW TW095140163A patent/TWI411607B/zh not_active IP Right Cessation
- 2006-11-13 SG SG201101062-6A patent/SG169983A1/en unknown
- 2006-11-13 CA CA2628952A patent/CA2628952C/en not_active Expired - Fee Related
- 2006-11-13 US US12/084,928 patent/US8487108B2/en not_active Expired - Fee Related
- 2006-11-13 AU AU2006325322A patent/AU2006325322B2/en not_active Ceased
- 2006-11-13 NZ NZ568042A patent/NZ568042A/en not_active IP Right Cessation
- 2006-11-13 WO PCT/US2006/043920 patent/WO2007070201A1/en not_active Ceased
- 2006-11-13 PE PE2006001432A patent/PE20070804A1/es not_active Application Discontinuation
- 2006-11-13 AT AT06837406T patent/ATE538092T1/de active
- 2006-11-13 JP JP2008540236A patent/JP2009515893A/ja not_active Withdrawn
- 2006-11-13 BR BRPI0618585-1A patent/BRPI0618585A2/pt not_active IP Right Cessation
- 2006-11-13 KR KR1020087014407A patent/KR101379663B1/ko not_active Expired - Fee Related
- 2006-11-13 EP EP06837406A patent/EP1966139B1/en active Active
- 2006-11-14 AR ARP060104967A patent/AR057890A1/es unknown
-
2008
- 2008-05-07 NO NO20082108A patent/NO20082108L/no not_active Application Discontinuation
-
2010
- 2010-08-06 PE PE2010000496A patent/PE20120229A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080069685A (ko) | 2008-07-28 |
| SG169983A1 (en) | 2011-04-29 |
| JP2009515893A (ja) | 2009-04-16 |
| EP1966139A1 (en) | 2008-09-10 |
| HK1121459A1 (en) | 2009-04-24 |
| EP1966139B1 (en) | 2011-12-21 |
| US8487108B2 (en) | 2013-07-16 |
| AU2006325322B2 (en) | 2011-08-04 |
| PE20070804A1 (es) | 2007-09-06 |
| AR057890A1 (es) | 2007-12-26 |
| CA2628952C (en) | 2014-04-01 |
| US20100048636A1 (en) | 2010-02-25 |
| BRPI0618585A2 (pt) | 2011-09-27 |
| WO2007070201A1 (en) | 2007-06-21 |
| NO20082108L (no) | 2008-08-06 |
| KR101379663B1 (ko) | 2014-04-14 |
| NZ568042A (en) | 2010-12-24 |
| TW200800893A (en) | 2008-01-01 |
| CA2628952A1 (en) | 2007-06-21 |
| PE20120229A1 (es) | 2012-04-04 |
| AU2006325322A1 (en) | 2007-06-21 |
| TWI411607B (zh) | 2013-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2017010I1 (lt) | Proteazomos inhibitoriai | |
| ATE530554T1 (de) | Serinprotease-hemmer | |
| ATE482214T1 (de) | Aspartylproteasehemmer | |
| BRPI0807547A2 (pt) | Inibidores de aspartil protease hetercíclicos | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| NO20076678L (no) | Glutamataggrekanaseinhibitorer | |
| DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
| LTPA2016036I1 (lt) | Nitrokatechnolio dariniai, kaip COMT inhibitoriai | |
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| DK1848718T3 (da) | E1 aktiveringsenzymhæmmere | |
| ATE478070T1 (de) | Heterozyklische aspartyl-proteasehemmer | |
| DK1934236T3 (da) | Heterobifunktionelle pan-selektininhibitorer | |
| DE502006006338D1 (de) | Ächen | |
| DK2032535T3 (da) | Spiro-cycliske nitriler som protease-inhibitorer | |
| NL350097I2 (nl) | Cerevisane | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
| IL183850A0 (en) | Hiv protease inhibitors | |
| EP2064177A4 (en) | PROTEASE INHIBITORS | |
| ATE545642T1 (de) | Mmp-inhibitoren | |
| DK1865940T3 (da) | Alfaketoamidforbindelser som cysteinproteasehæmmere | |
| EP1921078A4 (en) | Multikinase inhibitor | |
| DK2331548T3 (da) | Proteasehæmmere | |
| ATE418545T1 (de) | Nnrt-inhibitoren | |
| EP1855672A4 (en) | HIV PROTEASE INHIBITORS |